Diagnosis and management of multiple sclerosis

American Family Physician

Volumn 70, Issue 10, 2004, Pages 1935-1944

  Calabresi, Peter A ^a,b,c,d,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c STRONG MEMORIAL HOSPITAL   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e National Multiple Sclerosis Society   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; AZATHIOPRINE; BACLOFEN; BENZODIAZEPINE; BETA1 INTERFERON; BETHANECHOL; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESMOPRESSIN; DOXAZOSIN; GABAPENTIN; GADOLINIUM; GLATIRAMER; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MODAFINIL; NATALIZUMAB; OXYBUTYNIN; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TAMSULOSIN; TERAZOSIN; TIZANIDINE; TOLTERODINE; UNINDEXED DRUG;

ALOPECIA; ANEMIA; ANXIETY; BLADDER DYSFUNCTION; BRAIN INJURY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM INFECTION; CHILL; CLINICAL FEATURE; CYANOCOBALAMIN DEFICIENCY; DEPRESSION; DIAGNOSTIC ERROR; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DYSPNEA; ERECTILE DYSFUNCTION; FATIGUE; FECES INCONTINENCE; FEVER; FLU LIKE SYNDROME; FLUSHING; HEART PALPITATION; HISTOPATHOLOGY; HUMAN; LABORATORY DIAGNOSIS; LEUKEMIA; LYME DISEASE; MALAISE; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; REVIEW; SARCOIDOSIS; SJOEGREN SYNDROME; SPASTICITY; SPINAL CORD COMPRESSION; SPINAL CORD LESION; SYPHILIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VASCULAR DISEASE;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; HUMANS; MULTIPLE SCLEROSIS;

EID: 8844244694     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
2. Arnold DL, Matthews PM. MRI in the diagnosis and management of multiple sclerosis. Neurology 2002;58(8 suppl 4):S23-31.
3. Chiappa KH. Pattern-shift visual, brainstem auditory and short-latency somatosensory evoked potentials in multiple sclerosis. Ann N Y Acad Sci 1984;436:315-27.
4. Cole SR, Beck RW, Moke PS, Kaufman DI, Tourtellotte WW. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group. Neurology 1998;51:885-7.
5. Rudick RA, Schiffer RB, Schwetz KM, Herndon RM. Multiple sclerosis. The problem of incorrect diagnosis. Arch Neurol 1986;43:578-83.
6. Cutter NC, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000;81:164-9.
7. Sampson FC, Hayward A, Evans G, Morton R, Collett B. Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity. J Neurosurg 2002;96:1052-7.
8. Bhatia. KP. The paroxysmal dyskinesias. J Neurol 1999;246:149-55.
9. Beydoun A, Kutluay E. Oxcarbazepine. Expert Opin Pharmacother 2002;3:59-71.
10. Appell RA, Sand P, Dmochowski R, Anderson R, Zinner N, Lama D, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76:358-63.
11. O'Riordan JI, Doherty C, Javed M, Brophy D, Hutchinson M, Quinlan D. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol 1995;153:1114-6.
12. Hatzichristou DG. Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impot Res 2002;14(suppl 1):S43-52.
13. Feinstein A, Feinstein K. Depression associated with multiple sclerosis. Looking beyond diagnosis to symptom expression. J Affect Disord 2001;66:193-8.
14. Krupp LB, Rizvi SA. Symptomatic therapy for underrecognized manifestations of multiple sclerosis. Neurology 2002;58(8 suppl 4):S32-9.
15. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002;72:179-83.
16. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-6.
17. Patti F, Ciancio MR, Reggio E, Lopes R, Palermo F, Cacopardo M, et al. The impact of outpatient rehabilitation on quality of life in multiple sclerosis. J Neurol 2002;249:1027-33.
18. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS [published correction appears in Neurology 2001;57:1146] Neurology 2001;56:1628-36.
19. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-7.
20. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998;43:79-87.
21. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999;46:197-206.
22. Rice GP, Oger J, Duquette P, Francis GS, Belanger M, Laplante S, et al. Treatment with interferon beta-1b improves quality of life in multiple sclerosis. Can J Neurol Sci 1999;26:276-82.
23. Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000;48:885-92.
24. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002;59:1496-506.
25. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60.
26. Double-blind randomized multicenter dose-comparison study of interferon-beta-1a (AVONEX): rationale, design and baseline data. Mult Scler 2001;7:179-83.
27. Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M, et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry 2002;73:148-53.
28. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701-8.
29. Comi G, Fillppi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:290-7.
30. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76.
31. Brenner T, Arnon R, Sela M, Abramsky O, Meiner Z, Riven-Kreitman R, et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001;115:152-60.
32. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-25.
33. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
34. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, et al. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 1998;50:398-402.
35. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338:1051-5.
36. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37:30-40.
37. Calabresi PA, Wilterdink JL, Rogg JM, Mills P, Webb A, Whartenby KA. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002;58:314-7.
38. Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler 2002;8:142-54.
39. Coyle PK, Hartung HP. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult Scler 2002;8:2-9.
40. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85.
41. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
42. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandex O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82.
43. National Multiple Sclerosis Society, Disease management consensus statement. Accessed online September 1, 2004, at http://www.nationalmssociety. org/pdf/for-pros/Exp_Consensus.pdf.
44. Filippi M, Grossman RI. MRI techniques to monitor MS evolution: the present and the future. Neurology 2002;58:1147-53.